|
| Author (year) | Country | Defines symptom | Criteria to assess symptom | Risk stratification | Self-care to manage symptom | Followup for ongoing monitoring | Other recommendations in guideline | Rigour score
(raters would recommend) |
|
| Hughes et al. (2002) [41] | USA |
≥38.3°C or ≥38°C for 1 hour and <500 cell/mm3 or <1000 cell/mm3 and expected to drop | See scoring index on Table 4 of Hughes et al. (2002) [41] | Scoring index on Table 4 of the paper for MASCC risk index | — | — | Use of prescribed medications | 62 (4/4) |
| NCCN (2008) [40] | USA | Refers to Hughes
et al. [41] | Temperature, neutrophil count | MASCC risk index | — | — | Use of prescribed medications | 48 (2/4) |
| Mendes et al. (2007) [43] | Brazil | Refers to Hughes
et al. [41] | Temperature, neutrophil count, sepses | Infectious diseases working group, German Society of Haematology and Oncology | — | Reassess in 12 to 24 hours if neutropenia only | Use of prescribed medications | 33 (4/4) |
| Cancer Care Ontario (2004) [37] | Canada | ≥38°C | Many items (temperature, chills, other symptoms, etc.) | Nonurgent, urgent, emergent | Monitor temperature; minimize infection risk | Take temperature every 2–4 hours | — | 23 (2/4) |
| Gaillet (2007) [42] | France | Excluded due to low quality score; no data extracted | 14 (0/4) |
|
